TNFSF10 and neoplasm: Results showed a significant (p < 0,05) reduction of tumor growth in the RGT (RG7112 plus rhTRAIL) groups compared to mock-treated at the 15th and 22th days time points, while we observed no antitumor effect of RG7112 and TRAIL administered as single agents.